6,727 Shares in Arvinas, Inc. (NASDAQ:ARVN) Purchased by Cornercap Investment Counsel Inc.

Cornercap Investment Counsel Inc. bought a new stake in Arvinas, Inc. (NASDAQ:ARVN) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 6,727 shares of the company’s stock, valued at approximately $277,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ARVN. China Universal Asset Management Co. Ltd. grew its position in shares of Arvinas by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,374 shares of the company’s stock valued at $27,000 after acquiring an additional 674 shares during the period. BluePath Capital Management LLC bought a new position in shares of Arvinas during the 3rd quarter valued at approximately $28,000. PNC Financial Services Group Inc. grew its position in shares of Arvinas by 1,015.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,383 shares of the company’s stock valued at $34,000 after acquiring an additional 1,259 shares during the period. Royal Bank of Canada grew its position in shares of Arvinas by 37.6% during the 3rd quarter. Royal Bank of Canada now owns 1,230 shares of the company’s stock valued at $54,000 after acquiring an additional 336 shares during the period. Finally, Natixis bought a new position in shares of Arvinas during the 4th quarter valued at approximately $54,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Arvinas news, CEO John G. Houston sold 5,196 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $244,471.80. Following the sale, the chief executive officer now owns 1,036,681 shares of the company’s stock, valued at approximately $48,775,841.05. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO John G. Houston sold 5,196 shares of the firm’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $244,471.80. Following the completion of the sale, the chief executive officer now directly owns 1,036,681 shares of the company’s stock, valued at approximately $48,775,841.05. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ronald Peck sold 1,699 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $47.05, for a total transaction of $79,937.95. Following the completion of the sale, the insider now directly owns 67,516 shares of the company’s stock, valued at $3,176,627.80. The disclosure for this sale can be found here. Insiders have sold a total of 8,597 shares of company stock valued at $404,489 in the last quarter. Insiders own 2.55% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on ARVN. HC Wainwright reduced their target price on shares of Arvinas from $90.00 to $87.00 and set a “buy” rating for the company in a research report on Friday, April 12th. Wedbush increased their target price on shares of Arvinas from $33.00 to $59.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. Oppenheimer restated an “outperform” rating and set a $80.00 price target (down from $95.00) on shares of Arvinas in a research note on Wednesday, February 28th. Barclays upped their price target on shares of Arvinas from $26.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. Finally, BMO Capital Markets upped their price target on shares of Arvinas from $89.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $59.73.

Arvinas Price Performance

Shares of NASDAQ:ARVN opened at $33.45 on Thursday. The company’s fifty day moving average price is $43.86 and its 200-day moving average price is $33.94. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -5.15 and a beta of 1.94. Arvinas, Inc. has a one year low of $13.57 and a one year high of $53.08.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 27th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($1.15) by ($1.38). Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. The business had revenue of ($43.10) million for the quarter, compared to the consensus estimate of $38.91 million. During the same period in the prior year, the business posted ($1.56) EPS. As a group, equities research analysts expect that Arvinas, Inc. will post -5.02 EPS for the current year.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.